C4 therapeutics announces license and research collaboration with merck to discover and develop degrader-antibody conjugates (dacs)

Initial focus on one oncology target, exclusive to collaboration; merck has option for three additional targets initial focus on one oncology target, exclusive to collaboration; merck has option for three additional targets

CCCC Ratings Summary

CCCC Quant Ranking